NEELS GUIDO J — SEC insider filings
SEC reporting owner CIK 1222362. 29 insider filings on record with FilingPulse; latest filed 2026-11-12.
Transaction summary — filings shown
Covers all 29 filings on record, filed 2020-09-08 to 2026-11-12. Counts and totals are arithmetic on values as filed — descriptive data, not a recommendation.
- Open-market purchases (code P, non-derivative): 4 legs across 3 filings — 60,000 shares, $113,700 total (shares × price as filed).
- Open-market sales (code S, non-derivative): 1 leg across 1 filing — 4,073 shares, $43,215 total (shares × price as filed).
- Other reported legs (grants, option exercises, tax withholding, gifts, derivative-security transactions, …): 55.
- Largest priced transaction: purchase of 10,000 shares @ $6.11 ($61,100) in Axogen, Inc., filed 2023-08-18.
By issuer — same filings
Open-market purchase/sale legs on non-derivative securities, grouped by issuer. Role is as filed on the newest filing for that issuer. Dollar totals cover priced legs only (shares × price as filed). Ordered by priced transaction value, largest first.
| Issuer | Role (as filed) | Filings | Purchases (P) | Sales (S) | Other legs |
|---|---|---|---|---|---|
| Axogen, Inc. (AXGN) | Director | 11 | 1 leg · 10,000 sh · $61,100 | 1 leg · 4,073 sh · $43,215 | 25 |
| ELUTIA INC. (ELUT) | Director | 7 | 3 legs · 50,000 sh · $52,600 | — | 7 |
| Bioventus Inc. (BVS) | Director | 10 | — | — | 19 |
| TELA Bio, Inc. (TELA) | Director | 1 | — | — | 4 |
Insider filings — NEELS GUIDO J
| Filed | Form | Issuer | Reported transactions | Source |
|---|---|---|---|---|
| 2026-11-12 | 4 | ELUTIA INC. (ELUT) | Grant/award (A): 117,000 (derivative) @ $0 | EDGAR |
| 2026-06-15 | 4 | ELUTIA INC. (ELUT) | Grant/award (A): 106,393 (derivative) @ $0 | EDGAR |
| 2026-06-11 | 4 | TELA Bio, Inc. (TELA) | Grant/award (A): 11,925 @ $0 · Grant/award (A): 11,675 @ $0 · Grant/award (A): 17,550 (derivative) @ $0 · Grant/award (A): 17,335 (derivative) @ $0 | EDGAR |
| 2026-06-04 | 4 | Bioventus Inc. (BVS) | Option exercise (M): 32,282 @ $0 · Option exercise (M): 32,282 (derivative) @ $0 · Grant/award (A): 25,146 (derivative) @ $0 | EDGAR |
| 2026-04-14 | 4 | ELUTIA INC. (ELUT) | Option exercise (M): 6,250 · Option exercise (M): 6,250 (derivative) @ $0 | EDGAR |
| 2026-02-02 | 4 | ELUTIA INC. (ELUT) | Purchase (P): 20,000 @ $1.04 | EDGAR |
| 2026-01-29 | 4 | ELUTIA INC. (ELUT) | Purchase (P): 15,000 @ $1.06 · Purchase (P): 15,000 @ $1.06 | EDGAR |
| 2025-12-02 | 4 | ELUTIA INC. (ELUT) | Option exercise (M): 6,250 · Option exercise (M): 6,250 (derivative) @ $0 | EDGAR |
| 2025-10-14 | 4 | ELUTIA INC. (ELUT) | Grant/award (A): 171,916 (derivative) @ $0 | EDGAR |
| 2025-06-11 | 4 | Axogen, Inc. (AXGN) | Sale (S): 4,073 @ $10.61 | EDGAR |
| 2025-06-04 | 4 | Bioventus Inc. (BVS) | Option exercise (M): 26,493 @ $0 · Option exercise (M): 26,493 (derivative) @ $0 · Grant/award (A): 32,282 (derivative) @ $0 | EDGAR |
| 2024-09-04 | 4 | Axogen, Inc. (AXGN) | Option exercise (M): 11,904 @ $0 · Option exercise (M): 11,904 (derivative) @ $0 | EDGAR |
| 2024-06-13 | 4 | Bioventus Inc. (BVS) | Grant/award (A): 26,493 (derivative) @ $0 | EDGAR |
| 2024-06-11 | 4 | Bioventus Inc. (BVS) | Option exercise (M): 30,400 @ $0 · Option exercise (M): 30,400 (derivative) @ $0 | EDGAR |
| 2024-06-10 | 4 | Axogen, Inc. (AXGN) | Grant/award (A): 10,653 · Grant/award (A): 18,248 (derivative) @ $0 | EDGAR |
| 2023-09-07 | 4 | Axogen, Inc. (AXGN) | Grant/award (A): 20,436 (derivative) @ $0 · Grant/award (A): 11,904 (derivative) @ $0 | EDGAR |
| 2023-08-18 | 4 | Axogen, Inc. (AXGN) | Purchase (P): 10,000 @ $6.11 | EDGAR |
| 2023-06-08 | 4 | Bioventus Inc. (BVS) | Option exercise (M): 16,648 @ $0 · Option exercise (M): 16,648 (derivative) @ $0 · Grant/award (A): 30,400 (derivative) @ $0 | EDGAR |
| 2023-06-05 | 4 | Axogen, Inc. (AXGN) | Option exercise (M): 6,459 @ $0 · Option exercise (M): 6,459 (derivative) @ $0 | EDGAR |
| 2022-06-22 | 4 | Bioventus Inc. (BVS) | Grant/award (A): 16,648 (derivative) @ $0 | EDGAR |
| 2022-06-03 | 4 | Axogen, Inc. (AXGN) | Option exercise (M): 3,036 @ $0 · Option exercise (M): 3,036 (derivative) @ $0 · Grant/award (A): 11,811 (derivative) @ $0 · Grant/award (A): 6,459 (derivative) @ $0 | EDGAR |
| 2022-04-05 | 4 | Bioventus Inc. (BVS) | Option exercise (M): 2,700 · Option exercise (M): 2,700 (derivative) @ $0 | EDGAR |
| 2022-02-15 | 4 | Bioventus Inc. (BVS) | Option exercise (M): 9,000 · Option exercise (M): 9,000 (derivative) @ $0 | EDGAR |
| 2021-06-07 | 4/A | Axogen, Inc. (AXGN) | Option exercise (M): 25,000 @ $3.80 · Option exercise (M): 15,000 @ $5.09 · Option exercise (M): 25,000 (derivative) @ $3.80 · Option exercise (M): 15,000 (derivative) @ $5.09 | EDGAR |
| 2021-06-03 | 4 | Axogen, Inc. (AXGN) | Option exercise (M): 6,173 @ $0 · Option exercise (M): 6,173 (derivative) @ $0 · Grant/award (A): 6,030 (derivative) @ $0 · Grant/award (A): 3,036 (derivative) @ $0 | EDGAR |
| 2021-05-21 | 4 | Axogen, Inc. (AXGN) | Option exercise (M): 25,000 @ $3.80 · Option exercise (M): 15,000 @ $5.09 · Option exercise (M): 25,000 (derivative) @ $3.80 · Option exercise (M): 15,000 (derivative) @ $5.09 | EDGAR |
| 2021-04-05 | 4 | Bioventus Inc. (BVS) | Grant/award (A): 2,700 (derivative) @ $0 | EDGAR |
| 2021-02-16 | 4 | Bioventus Inc. (BVS) | Grant/award (A): 9,000 (derivative) @ $0 | EDGAR |
| 2020-09-08 | 4 | Axogen, Inc. (AXGN) | Grant/award (A): 2,591 @ $11.75 | EDGAR |
FilingPulse's Form 4 archive currently extends back to 2020-09-04 and is expanding backward through EDGAR history; Forms 3 and 5 are covered live-forward since 2026-09-23 (no 3/5 history). Earlier filings by this insider may not be indexed yet. Names and roles are shown as filed.
GET https://api.filingpulse.io/v1/insider-trades?owner_cik=1222362 returns every filing on this page — normalized, with footnotes and derivative legs — and webhooks push new filings to you in seconds. Get a free API key → · API docs